Syros prioritizing oral CDK7, dropping IV after Phase I data

After tolerability issues in a Phase I trial led to lower doses and longer infusion times for its first clinical CDK7 inhibitor, Syros is choosing to concentrate instead on a preclinical oral compound aimed at the same target.

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) intends to start next quarter a Phase I trial in select solid tumors of SY-5609, its non-covalent oral

Read the full 591 word article

How to gain access

Continue reading with a
two-week free trial.